Overview

Update
Total Equity Funding
$65.89M in 2 Rounds from 4 Investors
Most Recent Funding
$29.89M Series B on June 22, 2015
Headquarters:
Ann Arbor, MI
Description:
Lycera engages in the development of small-molecule immunomodulators for the treatment of patients with autoimmune diseases.
Founders:
Categories:
Pharmaceutical, Biopharma, Biotechnology
Website:
http://www.lycera.com
Social:

Company Details

Update

Lycera isa preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease Lycera's first-in-class drugs are designed to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.

Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.

Funding Rounds (4) - $74.89M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jun, 2015$29.89M / Series B0
Apr, 2014$4M / Debt Financing0
Oct, 2013$5M / Debt Financing0
May, 2009$36M / Series A4

Current Team (7)

Update

Offices/Locations (1)

Update
  • Lycera

    2800 Plymouth Rd.

    NCRC, Building 26

    Ann Arbor, MI 48109

    USA

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos